je.st
news
Genelux announces promising data from two phase I trials of GL-ONC1...
2015-05-28 22:50:38| Logistics - Topix.net
Genelux Corporation, a clinical-stage biopharmaceutical company focused on the development of vaccinia virus for oncolytic immunotherapy, today announced that data from two Phase I trials evaluating its lead oncolytic virotherapy GL-ONC1 in head and neck cancer and malignant pleural mesothelioma demonstrate a favorable safety profile and support further investigation of the therapy in both indications. The results will be presented by lead investigators from Memorial Sloan Kettering Cancer Center and UC San Diego Moores Cancer Center at the upcoming 2015 American Society of Clinical Oncology Annual Meeting, being held May 29-June 2 in Chicago, IL.
Tags: of
data
phase
trials
Category:Transportation and Logistics
Latest from this category |
All news |
||||||||||||||||||
|
|||||||||||||||||||